ADHERA

Adhera Therapeutics is a specialty pharmaceutical company focused on the development of innovative therapies for neurological conditions and movement disorders. The company's lead clinical candidate, ML-007 (cevimeline), is a muscarinic receptor agonist being investigated for its potential to treat autonomic dysfunction and other symptoms associated with Parkinson's disease. Adhera utilizes the 505(b)(2) regulatory pathway to repurpose established compounds, aiming to reduce the time and cost of drug development by leveraging existing safety data. Formerly known as Marina Biotech, the company has transitioned from a focus on RNA therapeutics to a specialty pharmaceutical model targeting unmet needs in the CNS space.